Circulating tumor DNA (ctDNA) kinetics to predict survival in patients (pts) with unresectable or metastatic melanoma treated with dabrafenib (D) or D + trametinib (T).

Mahrukh M. Syeda,Jennifer M. Wiggins,Broderick Corless,Georgina V. Long,Keith T. Flaherty,Dirk Schadendorf,Paul Nathan,Caroline Robert,Antoni Ribas,Michael A. Davies,Jean-Jacques Grob,Eduard Gasal,Matthew Squires,Mahtab Marker,Jan C. Brase,David Polsky

Circulating tumor DNA (ctDNA) kinetics to predict survival in patients (pts) with unresectable or metastatic melanoma treated with dabrafenib (D) or D + trametinib (T).

2019

Mahrukh M. Syeda
Jennifer M. Wiggins
Broderick Corless
Georgina V. Long
Keith T. Flaherty
Dirk Schadendorf
Paul Nathan
Caroline Robert
Antoni Ribas
Michael A. Davies
Jean-Jacques Grob
Eduard Gasal
Matthew Squires
Mahtab Marker
Jan C. Brase
David Polsky

9510Background: There are no validated blood-based biomarkers to monitor efficacy in pts with advanced melanoma. Lactate dehydrogenase (LDH) is an established prognostic factor; however, it is not ...

Keywords:

Circulating tumor DNA
Trametinib
Melanoma
Kinetics
Cancer research
Dabrafenib
Pathology
Medicine
in patient
Biomarker (medicine)
prognostic factor
Lactate dehydrogenase
metastatic melanoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations